The low humidity drug stability test chamber and drug strong light stability test chamber of Lanbeishi are used in multiple subsidiaries of Kelun (Hunan, Hubei, Henan, Guizhou, Yunnan)

Kelun Group Founded in 1996, after more than 20 years of development, it has now become a modern pharmaceutical group with over 100 enterprises at home and abroad. The industrial sector of the group, Kelun Pharmaceutical (SZ002422), was successfully listed on the Shenzhen Stock Exchange on June 3, 2010Large professional manufacturers and operators of infusion solutions are setting sail in the capital market.

In 2017, Kelun Group's operating revenue exceeded 40 billion yuan and its profits and taxes exceeded 3 billion yuan. According to the 2012 sales ranking of China's pharmaceutical distribution industry released by the Ministry of Commerce and the annual pharmaceutical statistics report of the Ministry of Industry and Information Technology, both the commercial and industrial sectors under the Kelun Group have entered the market1 0Strong.

As an industrial sector under the Kelun Group, Kelun Pharmaceutical produces and sells 598 varieties and 996 specifications of products, including large volume injections (infusion), small volume injections (water injection), sterile powder injections for injection (including packaged powder injections and freeze-dried powder injections), tablets, capsules, granules, oral liquids, peritoneal dialysis liquids, as well as raw materials, pharmaceutical packaging materials, medical devices, and antibiotic intermediates. Among them, it has 118 varieties and 280 specifications of infusion products, 385 varieties and 616 specifications of other dosage forms of pharmaceutical products, 47 varieties and 49 specifications of active pharmaceutical ingredients, 10 varieties of antibiotic intermediates, 34 varieties of pharmaceutical packaging materials, and 4 varieties and 7 specifications of medical device products. It is one of the pharmaceutical manufacturing enterprises in China's infusion industry with relatively complete varieties and packaging forms. In terms of specific products, the company has 121 varieties included in the National Essential Medicines List, making it a large pharmaceutical group with a relatively complete industrial chain in China.

In September 2008, the company was jointly awarded the 2008 China Pharmaceutical Enterprise Social Responsibility Contribution Award by the China Pharmaceutical Enterprise Management Association and the People's Daily Network Center; In 2008, the company was awarded the title of "Demonstration Enterprise of High tech Industry (Backbone Category, New Materials Field) in Sichuan Province" by the People's Government of Sichuan Province; On December 30, 2008, the company was jointly recognized as a "high-tech enterprise" by the Science and Technology Department, Finance Department, State Taxation Bureau, and Local Taxation Bureau of Sichuan Province; In August 2009, the China Pharmaceutical Packaging Association awarded the company the "Outstanding Contribution Unit Award for China's Pharmaceutical Packaging Industry"; On October 30, 2009, the Ministry of Science and Technology approved the establishment of the "National Large Capacity Injection Engineering Technology Research Center" by the company, which was included in the project plan for the establishment of the National Engineering Technology Research Center in 2009; On November 6, 2009, the company was jointly approved by the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Finance, the General Administration of Customs, and the State Administration of Taxation as a "nationally recognized enterprise technology center"; In April 2011, the company was jointly approved by the Ministry of Science and Technology, the State owned Assets Supervision and Administration Commission of the State Council, and the All China Federation of Trade Unions as the "Third Batch of National Innovative Enterprises"; In June 2011, the company was jointly recognized as a "National Technology Innovation Demonstration Enterprise" by the Ministry of Industry and Information Technology and the Ministry of Finance, becoming a pharmaceutical enterprise in Sichuan Province to receive this honor; In November 2011, the National Development and Reform Commission approved the establishment of the "National Local Joint Engineering Laboratory" by the company; In 2013, the company was rated as a "Demonstration Enterprise for Industrial Brand Cultivation" and a "Demonstration Enterprise for Deep Integration of Informatization and Industrialization" by the Ministry of Industry and Information Technology of China, and as a "Contract abiding and Creditworthy Enterprise" by the State Administration for Industry and Commerce; In May 2014, the company was recognized by the Ministry of Industry and Information Technology of China as a "pilot enterprise for the implementation of the integration of information and technology management system", becoming a pharmaceutical enterprise in Sichuan Province to receive this honor; In September 2015, the company was awarded the title of "2015 National Industrial Enterprise Quality * *" by the Ministry of Industry and Information Technology of China; In 2016, the company was awarded the title of "2015 Industrial Enterprise Intellectual Property Application" by the Ministry of Industry and Information Technology of China**”； In August 2017, the company was recognized by the Ministry of Industry and Information Technology as a "2017 Demonstration Enterprise for the Implementation of the Integration of Informatization and Industrialization Management System"; In August 2018, the company passed the GMP certification of PMDA in Japan, indicating that its products have obtained the qualification to be sold in Japan. The company has also been jointly evaluated as a Sichuan Provincial Academician (Expert) Workstation by the Organization Department of the Sichuan Provincial Party Committee, the Provincial Economic and Information Commission, the Provincial State owned Assets Supervision and Administration Commission, the Provincial Department of Education, the Provincial Department of Science and Technology, the Provincial Department of Human Resources and Social Security, and the Provincial Association for Science and Technology.

Since its establishment, Kelun Pharmaceutical has invested hundreds of millions of yuan in independent research and development, and has already mastered the core technology of infusion production. In 2005, Kelun Pharmaceutical independently developed a standing bag with multiple ZL technologies ® Successfully launched, this product embodies the new achievements of contemporary Chinese infusion manufacturing technology, representing the future development direction of infusion packaging materials in China and profoundly changing the landscape of the infusion industry. In November 2008, the company was able to produce bags ® It has been jointly recognized as a "National Key New Product" by the Ministry of Science and Technology, the Ministry of Environmental Protection, the Ministry of Commerce, and the General Administration of Quality Supervision, Inspection and Quarantine. In 2011, Ke Li Bag ® Was awarded the "First Prize for Science and Technology Progress in Sichuan Province" and the "Special Prize for Science and Technology Progress in Chengdu City". In 2015, Ke Li Bags ® Received the National Science and Technology Progress Award. Can stand bag ® Infusion has significant promotional value in ensuring the safety of medication and energy conservation and environmental protection for the people. Its airdrop capability played an irreplaceable role in the rescue work of the Wenchuan earthquake on May 12th. As an "unbreakable" infusion product, it was urgently airdropped to the disaster area, saving countless lives. In June 2013, the China Intellectual Property Index Report Research Group, jointly composed of the Ministry of Commerce, the State Intellectual Property Administration, and the China Securities Regulatory Commission, released the "Intellectual Property Report of Listed Companies in the Chinese Pharmaceutical Industry". The report shows that in 2013, 76 A-share listed companies (sample companies in the pharmaceutical industry) were evaluated based on their main business revenue, profit, R&D expenses as a percentage of operating revenue, total zl applications, total zl authorizations, and total domestic trademarks. Kelun Pharmaceutical's zl application and zl authorization numbers were both No. 1Kelun has already stood on the starting line of new technology.

Kelun Pharmaceutical adheres to the corporate philosophy of "seeking truth through science and seeking goodness through ethics", and has established a harmonious development awareness of primary distribution based on efficiency, secondary distribution based on government finance and taxation, and tertiary distribution based on social charity. Over the years, Kelun has donated more than 100 million yuan to social welfare, honorable cause, and charity, demonstrating Kelun's wealth quality concept and sense of social justice, and showcasing a good image of an excellent private enterprise developing healthily under market economy conditions. Especially after the Wenchuan earthquake on May 12th, Kelun Pharmaceutical, together with the people of the whole country, made every effort to resist the earthquake and provide disaster relief; It is one of the first enterprises to open up the land route for rescuing drugs and implement emergency airdrops; It is an enterprise that perseveres in production and self rescue under immense pressure amidst continuous aftershocks; It is one of the enterprises that provide support to all international medical teams for earthquake relief and disaster relief in Sichuan. China Medical News, Medical Economy News, and other * * media have conducted in-depth reports on the command efficiency, logistical support, professional capabilities, and combat spirit of Kelun Pharmaceutical. In May 2009, in view of the outstanding performance of Kelun Pharmaceutical in the earthquake relief efforts during the "5.12" Wenchuan earthquake****The General Logistics Department, the Ministry of Health, the Mobilization Office of the National Development and Reform Commission, and the State Food and Drug Administration jointly awarded the company a "thank-you letter"; Liu Gengxin, Chairman of Kelun Pharmaceutical, was awarded the title of "Outstanding Communist Party Member in Earthquake Relief" by the Sichuan Provincial Party Committee and Chengdu Municipal Party Committee, and the honorable title of "Sichuan Province Earthquake Relief *" by the Sichuan Provincial Party Committee and Provincial Government. On April 20, 2013, a 7.0 magnitude earthquake struck Lushan County, Ya'an City, Sichuan Province. When the disaster struck again, Kelun Pharmaceutical once again gathered. Half an hour after the earthquake, Kelun Pharmaceutical contacted the Ya'an Health Bureau and confirmed the list of Kelun's first batch of donated drugs; Two hours after the earthquake, Chairman Liu Gengxin personally led his team and supplies to rush to the Ya'an disaster area. On June 24, 2017, a high-level collapse occurred in Xinmo Village, Diexi Town, Mao County, Aba Prefecture, Sichuan Province. After the disaster occurred, Kelun immediately took action and extended a helping hand, donating 3 million yuan to the disaster area. At the same time, Mr. Liu Gengxin, the chairman, donated 3 million yuan to the disaster area with his own funds in his personal name to support post disaster reconstruction.

After the deep integration of Kelun Pharmaceutical and the capital market, it will surely create even more magnificent follow-up performance. The company has further formulated a development strategy of "three drivers": the first engine is to consolidate and strengthen the overall advantages of the injection product cluster, including large infusion solutions, through continuous industrial upgrading and variety structure adjustment, and continue to maintain Kelun's position in the infusion field; The second engine is to build a competitive advantage in the entire antibiotic industry chain from intermediates, APIs to formulations through innovative development and utilization of high-quality natural resources such as water, coal, and agricultural products, and to grasp the global discourse power of antibiotics; The third engine is to develop high-tech drugs such as excellent generic drugs, innovative small molecule drugs, new drug delivery systems, and biotechnology drugs through the construction of a research and development system and diversified technological innovation, accumulating a long-term foundation for the enterpriseDriving force.